Clinical Researchat Audubon Dermatology in New Orleans, LA

Clinical research and clinical trials are crucial for the discovery and testing of new therapies for disease treatment and prevention. Dr. Hooper and Dr. Jackson are highly committed to their specialty and their patients by consistently mastering the best and latest techniques and treatments in the evolving field of Dermatology. Dr. Hooper and Dr. Jackson have over forty years of combined experience in their specialty, therefore, they are frequently asked to participate as investigators in various clinical trials for FDA approval of new and advanced medications and treatments.


CLICK HERE to see if you qualify to participate in a currently enrolling clinical study at Audubon Dermatology.

Completed Clinical Research Studies
2020 - Novan - NI-MC304

Topical Berdazimer Gel, A Nitric Oxide-Releasing Macromolesule –  a phase 3 multi-center, randomized, double-blind, vehicle-controlled, parallel group study comparing the efficacy and safety of SB206 and vehicle gel applied once daily in the treatment of molluscum contagiosum

2020 - Taro - IVRC 2002

Topical Ivermectin – a multi-center, double-blind, randomized, placebo controlled, patallel-group study, comparing 1% ivermectin cream (Taro Pharmaceuticals U.S.A. Inc.) to 1% ivermectin cream (Soolantra) and both active treatments to a placebo control in the treatment of moderate to severe facial rosacea

2019 - Galderma - 43USSA1812

Poly-L-Lactic Acid Implant – a randomized, evaluator-blinded, no-treatment controlled, multi-center study to evaluate the effectiveness and safety of Sculptra Aesthetic for correction of cheek wrinkles

2019 - Arcutis - ARQ-151-302

Topical PDE-4 Inhibitor – a phase 3, 8-week, parallel group, double blind, vehicle-controlled study of the safety and efficacy of 0.3% ARQ-151 cream administered daily in subjects with chronic plaque psoriasis

2019 - Dermavant - DMVT-505-3003

Topical Non-Steroid, Therapeutic AhR-Modulating Agent – a long-term, open-label extension study to evaluate the safety and efficacy of 1% tapinarof cream for the treatment of plaque psoriasis in adults

2019 - Arcutis - ARQ-151-306

Topical PDE-4 Inhibitor – a phase 3, multi-center, open-label extension study of the long-term safety of 0.3% ARQ-151 Cream in subjects with chronic plaque psoriasis

2019 - Cara - CR845210-501

Oral Kappa Receptor Agonist – a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral difelikefalin (CR845) for moderate to severe pruritus in adults subjects with atopic dermatitis

2019 - Incyte - INCB-18424-303

Topical JAK inhibitor – a phase 3, double-blind, randomized, 8-week, vehicle-controlled efficacy and safety study of ruxolitinib cream followed by a long-term safety extension period in adolescents and adults with atopic dermatitis

2018 - BristolMeyersSquibb - IM011407

A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with Randomized Withdrawal and Retreatment to Evaluate the Efficacy and Safety of BMS-986165 in Subject with Moderate-to-Severe Plaque Psoriasis

2018 - BioPharmX - BPX-04-C07

A Double-Blind, Randomized, Vehicle-Controlled, Phase 2 Study to Assess the Safety and Efficacy of BPX-04 Minocycline Topical Gel in the Treatment of Inflammatory Lesions of Papulopustular Rosacea

2018 - UCB - PS0013

A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study with an Initial Treatment Period Followed by a Randomized-Withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects with Moderate to Severe Chronic Plaque Psoriasis

2018 - Endo - EN3835-304

Injectable Proteinase Hydrolyzes, the Triple-Helical Region of Collagen – A phase 3B, open-label, long-term study to evaluate the safety and temporal pattern of response of EN3835 In the treatment of edematous fibrosclerotic panniculopathy

2018 - UCB - PS0014

IL-17 Inhibitor – a multi-center, open-label study to assess the long-term safety, tolerability, and efficacy of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis

2018 - Sol-Gel - SGT-54-01

A Phase 3 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study of S5G4T-1 in the Treatment of Papulopustular Rosacea

2018 - Dr. Reddy's Laboratory - PPC-06-CD-004

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 24-Week Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate) Extended Release Tablets in Subjects with Moderate-to-Severe Plaque Psoriasis

2018 - Glenmark - GBR830-204

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of GBR 830 in Adult Subjects with Moderate to Severe Atopic Dermatitis

2018 - Endo - EN3835-302

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy

2018 - UCB - PS015

IL-17 Inhibitor – a multi-center, randomized, double blind, secukinumab-controlled, parallel-group study to evaluate the efficacy and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis

2017 - Mylan - CD-14-875

A Randomized, Prospective, Multicenter, Double Blind, Parallel Assignment, Placebo Controlled Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® (Pimecrolimus) Cream, 1% in Patients with Mild to Moderate Atopic Dermatitis

2017 - Dermira - DRM01B-ACN05

An Open-Label Study Assessing Long-Term Safety of Olumacostat Glasaretil Gel in Subjects with Acne Vulgaris

2017 - Foamix - FX2017-22

A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 for 12 Weeks in the Treatment of Moderate-to-Severe Acne Vulgaris

2017 - Foamix - FX2016-11

A Randomized, Multicenter, Double-blind, Vehicle-controlled Study to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam Compared to Vehicle in the Treatment of Facial Papulopustular Rosacea

2017 - Dermira - DRM01B-ACN04

A Randomized, Double-Blind, Vehicle-Controlled, Efficacy and Safety Study of Olumacostat Glasaretil Gel in Subjects with Acne Vulgaris

2017 - Foamix - FX2016-13

An Open-Label Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 for 40 weeks in the Treatment of Moderate to Severe Facial Papulopustular Rosacea (Study FX2016-13)

2017 - Galderma - RD.03.SPR.114322

A randomized, double-blind, multi-center, parallel-group, placebo-controlled dose-ranging study to assess the efficacy and safety of nemolizumab (CD14152) in moderate-to-severe atopic dermatitis subjects with severe pruritus receiving topical corticosteroids

2017 - Kinex - KX01-AK-003 004

A Phase 3, Double-Blind, Vehicle-Controlled, Randomized, Parallel Group, Multicenter, Efficacy and Safety Study of KX2-391 Ointment 1% in Adult Subjects with Actinic Keratosis on the Face or Scalp

2017 - DS Biopharma - DS107E-06

A Randomized, Double-blind, Vehicle-Controlled, Phase IIb Study to Assess the Efficacy and Safety of Topically Applied DS107 Cream to Adults with Mild to Moderate Atopic Dermatitis

2016 - GlaxoSmithKline - 203121

A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis

2016 - Sol-Gel - SGT-65-02

A Phase 2, Randomized, Multicenter, Double-Blind, Active and Vehicle Controlled Parallel-group Study Evaluating the Efficacy, Safety, and Tolerability of Products S6G5T-3 and S6G5T-1 for the Treatment of Acne Vulgaris for 12 Weeks

2016 - Actavis - ACTA/AZEL/2015

A Multicenter, Double-blind, Randomized, Parallel-group, Vehicle-Controlled Study to Evaluate the Safety and Clinical Equivalence of a Generic Azelaic Acid Foam, 15% and the Reference Listed Finacea® (Azelaic acid) Foam, 15% in Patients with Moderate Facial Rosacea

Audubon Dermatology LogoAudubon Dermatology Preloader